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Abstract
From 1 January to 31 December 2019, thirty-nine institutions around Australia participated in the 
Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2019 was to deter-
mine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resist-
ant, and to characterise the molecular epidemiology of the E. faecium isolates. Of the 1,361 unique 
episodes of bacteraemia investigated, 95.2% were caused by either E. faecalis (51.4%) or E. faecium 
(43.8%). Ampicillin resistance was not detected in E. faecalis but was detected in 91.1% of E. faecium. 
Vancomycin non-susceptibility was detected in 0.1% of E. faecalis and in 41.8% of E. faecium. Overall, 
45.4% of E. faecium harboured vanA and/or vanB genes. For the vanA/vanB positive E. faecium 
isolates, 49.1% harboured vanA genes only and 50.6% vanB genes; 0.3% harboured both vanA and 
vanB genes. The percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is 
substantially higher than that seen in most European countries. E. faecium consisted of 78 multilocus 
sequence types (STs), of which 75.0% of isolates were classified into six major STs containing ten or 
more isolates. All major STs belong to clonal cluster (CC) 17, a major hospital-adapted polyclonal 
E. faecium cluster. The predominant STs (ST1424, ST17, ST796, ST80, ST1421, and ST78) were found 
across most regions of Australia. The most prevalent clone was ST1424, which was identified in all 
regions except the Northern Territory and Western Australia. Overall, 51.4% of isolates belonging 
to the six predominant STs harboured vanA or vanB genes. In 2019, AESOP has shown that entero-
coccal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant high-level 
gentamicin-resistant vanA or vanB E. faecium which have limited treatment options.
Keywords: Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance sur-
veillance; Enterococcus faecium; Enterococcus faecalis; vancomycin-resistant enterococci (VRE); 
bacteraemia
Background
Globally, Enterococcus is thought to account 
for approximately 10% of all bacteraemias, and 
in North America and Europe is the fourth 
and fifth leading cause of sepsis respectively.1,2 
Although in the 1970s healthcare-associated 
enterococcal infections were primarily due to 
Enterococcus faecalis, there has been a steadily-
increasing prevalence of E. faecium nosocomial 
infections.3–5 Worldwide, the increase in noso-
comial E. faecium infections has primarily been 
due to the expansion of polyclonal hospital-
adapted clonal complex (CC) 17 strains. While 
innately resistant to many classes of antibiotics, 
E. faecium has demonstrated a remarkable 
capacity to evolve new antimicrobial resistances. 
In 2009, the Infectious Diseases Society of 
America highlighted E. faecium as one of the 
key problem bacteria or ESKAPE (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneu-
moniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Enterobacter species) pathogens 
requiring new therapies.6
Annual report
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The Australian Group on Antimicrobial 
Resistance (AGAR) is a network of laborato-
ries located across Australia that commenced 
surveillance of antimicrobial resistance in 
Enterococcus species in 1995.7 In 2011, AGAR 
initiated the Australian Enterococcal Sepsis 
Outcome Programme (AESOP).8,9 The objective 
of AESOP 2019 was to determine the proportion 
of E. faecalis and E. faecium bacteraemia isolates 
demonstrating antimicrobial resistance, with 
particular emphasis on:
1. Assessing susceptibility to ampicillin;
2. Assessing susceptibility to glycopeptides; and




Thirty-nine laboratories from all Australian 
states and mainland territories.
Collection period
From 1 January to 31 December 2019, the 39 
laboratories collected all enterococcal species 
isolated from blood cultures. Enterococci with 
the same species and antimicrobial susceptibil-
ity profiles isolated from a patient’s blood culture 
within 14 days of the first positive culture were 
excluded. A new enterococcal sepsis episode in 
the same patient was recorded if it was confirmed 
by a further culture of blood taken more than 14 
days after the initial positive culture. Data were 
collected on age, sex, dates of admission and dis-
charge (if admitted), and mortality at seven and 
30 days from date of blood culture collection. 
To avoid interpretive bias, no attempt was made 
to assign attributable mortality. Each episode of 
bacteraemia was designated as ‘hospital-onset’ if 
the first positive blood culture(s) in an episode 
was collected > 48 hours after admission.
Laboratory testing
Enterococcal isolates were identified to the spe-
cies level by the participating laboratories using 
matrix-assisted laser desorption ionization, 
MALDI (MALDI Biotyper [Bruker Daltonics, 
Germany] or Vitek-MS® [bioMérieux, France]), 
or by the Vitek2® (bioMérieux). Antimicrobial 
susceptibility testing was performed using 
the Vitek2® (bioMérieux) or the Phoenix™ 
(Becton Dickinson, USA) automated microbiol-
ogy systems according to the manufacturer’s 
instructions. Minimum inhibitory concentra-
tion (MIC) data and isolates were referred to 
the Antimicrobial Resistance and Infectious 
Diseases (AMRID) Research Laboratory at 
Murdoch University. Breakpoints as identi-
fied by the Clinical and Laboratory Standards 
Institute (CLSI)10 and European Committee on 
Antimicrobial Susceptibility Testing (EUCAST)11 
were utilised for interpretation. Linezolid- and 
daptomycin-non-susceptible isolates and van-
comycin-susceptible isolates which harboured 
vanA or vanB genes were retested by Etest® 
(bioMérieux) using the Mueller-Hinton agar 
recommended by the manufacturer. E. faecalis 
ATCC® 29212 was used as the control strain. 
Molecular testing was performed by whole 
genome sequencing (WGS) using the NextSeq® 
platform (Illumina, USA). Sequencing results 
were analysed using the Nullarbor pipeline.12
A chi-square test for comparison of two propor-
tions was performed and 95% confidence inter-
vals (95% CI) were determined using MedCalc 
for Windows, version 12.7 (MedCalc Software, 
Belgium).
Approval to conduct the prospective data collec-
tion was given by the research ethics committee 
associated with each participating laboratory.
Results
From 1 January to 31 December 2019, a total of 
1,361 unique episodes of enterococcal bacterae-
mia were identified. Although nine Enterococcus 
species were identified, 51.4% of isolates (699) 
were E. faecalis and 43.8% (596 isolates) were 
E. faecium. The remaining 66 enterococci were 
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identified either as E. casseliflavus (22 isolates), 
E. gallinarum (21 isolates), E. avium (13 isolates), 
E. hirae (3 isolates), E. raffinosus (3 isolates), 
E. durans (3 isolates), or E. thailandicus (1 isolate).
A significant difference was seen in patient sex 
(p < 0.0001), with 890 patients (65.4%) male 
(95% CI: 62.8–67.9). The average age of patients 
was 64 years, ranging from 0 to 102 years, with a 
median age of 69 years. The majority of episodes, 
52.9% (720/1,361), were community-onset (95% 
CI: 50.2–55.6). However, a significant difference 
(p < 0.0001) in place of onset was seen between 
E. faecium and E. faecalis, with only 30.2% (95% 
CI: 26.5–34.0) of E. faecium episodes being 
community-onset versus 69.7% (95% CI: 66.1–
73.1) for E. faecalis. All-cause mortality at 30 
days, where data were known, was 20.6% (95% 
CI: 18.2–23.1). There was a significant difference 
(p < 0.0001) in mortality between E. faecalis 
and E. faecium episodes (13.7% vs 26.4% respec-
tively), but not between vancomycin-susceptible 
and vancomycin-non-susceptible E. faecium 
episodes (24.0% vs 30.9% respectively, p = 0.17).
E. faecalis phenotypic susceptibility results 
Apart from erythromycin, tetracycline, cipro-
floxacin and high-level gentamicin, acquired 
resistance was rare amongst E. faecalis (Table 1). 
One isolate with a vancomycin MIC of 16 mg/L 
was considered intermediate by CLSI and resist-
ant by EUCAST interpretive criteria. One isolate 
with an ampicillin MIC of 8 mg/L was consid-
ered susceptible by CLSI criteria and interme-
diate by EUCAST criteria; van genes were not 
detected in this isolate. A total of 43 E. faecalis 
isolates (6.2%) were initially reported as linezolid 
non-susceptible (CLSI breakpoint > 2 mg/L). 
However by Etest®, 42 of the 43 isolates had a 
linezolid MIC of ≤ 2 mg/L and were therefore 
considered linezolid susceptible. The remain-
ing isolate with an MIC of 4 mg/L, although 
intermediate by CLSI criteria, was considered 
susceptible by EUCAST criteria. One isolate was 
initially reported as daptomycin resistant (≥ 8 
mg/L) by CLSI criteria, however this isolate was 
unavailable for confirmation by Etest®.
E. faecium phenotypic susceptibility results
The majority of E. faecium isolates were non-
susceptible to multiple antimicrobials including 
ampicillin, erythromycin, tetracycline, cipro-
floxacin, nitrofurantoin and high-level gen-
tamicin (Table 2). Overall, 249 isolates (41.8%) 
were phenotypically vancomycin non-suscep-
tible (MIC > 4 mg/L). One hundred and seven 
(18%) and 114 (19.2%) isolates were teicoplanin 
non-susceptible by CLSI and EUCAST criteria 
respectively. Nineteen (3.2%) isolates were 
initially reported as linezolid non-susceptible 
(CLSI breakpoint > 2 mg/L). However, by Etest®, 
15 of the 16 isolates had linezolid MICs of ≤ 2 
mg/L and therefore were considered susceptible. 
One isolate with an MIC of 3.0 mg/L by Etest®, 
although intermediate by CLSI criteria, was 
considered susceptible by EUCAST criteria.
Genotypic vancomycin susceptibility results
For 382 (54.7%) of the 699 E. faecalis isolates, 
vanA/vanB PCR results were available; vanA 
genes were not detected. One isolate which had 
a vancomycin MIC of 2 mg/L harboured vanB 
genes. WGS was not performed on the E. faecalis 
isolates.
The presence of vanA/vanB genes was deter-
mined by polymerase chain reaction (PCR) 
or WGS on 588 (98.7%) of the 596 E. faecium 
isolates. Overall, 267 of the 588 isolates (45.4%) 
harboured a vanA and/or vanB gene. One hun-
dred and 20 of the vancomycin-non-susceptible 
E. faecium isolates harboured vanA (Vitek® van-
comycin MIC > 4 mg/L). A further 128 E. faecium 
vancomycin non-susceptible isolates harboured 
vanB. One isolate harboured both vanA and 
vanB genes. vanA or vanB genes were detected 
in eighteen vancomycin-susceptible E. faecium 
isolates. Eleven isolates harboured vanA. These 
isolates had Vitek® vancomycin MICs ≤ 4.0mg/L; 
2.0 mg/L [5 isolates], 1.0 mg/L [5 isolates] and ≤ 
0.5 mg/L [1 isolate], and teicoplanin 2.0 mg/L (1 
isolate] and ≤ 1.0 mg/L [10 isolates]. Seven iso-
lates harboured vanB (Vitek® vancomycin MIC 
2.0 mg/L [7 isolates]).
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E. faecium molecular epidemiology
Of the 596 episodes, 568 E. faecium isolates 
(95.3%) were available for typing by WGS. The 
568 isolates were classified into 78 sequence 
types (STs), including six STs with 10 or more 
isolates (Table 3). Of the 72 STs with < 10 isolates, 
49 had only one isolate. Overall, 432 (75.0%) of 
the 568 isolates were grouped into the six major 
STs. Using eBURST, all major STs were grouped 
into CC 17.
Geographical distribution of the STs varied 
(Table 3). For the six major STs, ST1424 (133 
isolates) was identified in all regions except the 
Northern Territory and Western Australia; ST17 
(102 isolates) was identified in all regions except 
the Australian Capital Territory; ST796 (74 iso-
lates) in all regions except the Australian Capital 
Territory and the Northern Territory; ST80 (52 
isolates) in all regions except Tasmania; and 
ST1421 (49 isolates) and ST78 (22 isolates) were 
each found in all regions except the Northern 
Territory, South Australia, Tasmania and 
Western Australia.
In four major STs (118 isolates: ST1424, ST17, 
ST80 and ST1421), vanA was detected; vanB was 
detected in five major STs (103 isolates: ST1424, 
ST17, ST796, ST80, and ST78) (Table 4). One 
ST796 isolate harboured both vanA and vanB 
genes. Eight minor STs (9 isolates) harboured 
vanA genes and seven minor STs (25 isolates) 
harboured vanB genes.
Discussion
Enterococci are intrinsically resistant to a broad 
range of antimicrobials including the cepha-
losporins and sulphonamides. By their ability 
to acquire additional resistance through the 
transfer of plasmids and transposons, and to 
disseminate easily in the hospital environment, 
enterococci have become difficult to treat and 
provide major infection control challenges.
As the AGAR programs are similar to those 
conducted in Europe, comparison of Australian 
antimicrobial resistance data with other coun-
tries is possible.
In the 2018 European Centre for Disease 
Prevention and Control (ECDC) enterococci 
surveillance program, the European Union/
European Economic Area (EU/EEA) popula-
tion-weighted mean percentage of E. faecium 
resistant to vancomycin was 17.3% (95% CI: 
17–18), which represents a significant increase 
from 2014 when the percentage was 10.4%. 
The national percentages ranged from 0.0% in 
Iceland (95% CI: 0–21), Luxembourg (95% CI: 
0–12), and Slovenia (95% CI: 0–3) to 59.1% (95% 
CI: 43–74) in Cyprus.13
In AESOP 2019, 43.8% of enterococcal bacte-
raemia were due to E. faecium, of which 41.8% 
(95% CI: (37.8-45.9) were phenotypically vanco-
mycin non-susceptible by Vitek2® or Phoenix™. 
However, 45.4% of E. faecium isolates tested 
(265/588) harboured vanA/vanB genes, of which 
49.1% were vanA. Overall, 22.3% (131/588) of 
E. faecium isolates harboured the vanA gene. 
There has been a significant increase in vanA 
E. faecium in Australia over the AGAR sur-
veys 2013 to 2018, from 6% in 2013 to 26.1% in 
2018.14–19 The majority of E. faecium isolates were 
also non-susceptible to multiple antimicrobials, 
including ampicillin, erythromycin, tetracy-
cline, ciprofloxacin and high-level gentamicin. 
The AESOP surveys confirm the incidence of 
vancomycin-resistant E. faecium bacteraemia in 
Australia is a significant problem.
Seven of the 135 vanB E. faecium isolates (6.6%) 
and eleven (8.3%) of the 131 vanA E. faecium 
isolates had a vancomycin MIC at or below the 
CLSI and the EUCAST susceptible breakpoint 
(≤ 4 mg/L), and therefore would not have been 
identified using routine phenotypic antimicro-
bial susceptibility methods.
By WGS, E. faecium was shown to be very 
polyclonal, consistent with the known plastic-
ity of the enterococcal genome. The six major 
E. faecium STs form part of CC 17, a global 
hospital-derived lineage that has successfully 
adapted to hospital environments. The CC 
17 lineage is characteristically ampicillin and 
quinolone resistant, and subsequent acquisition 
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Table 4: The number and proportion of major Enterococcus faecium sequence types harbouring 
vanA/vanB genes, Australia, 2019
ST n
vanA vanB vanA and vanB Not detected
n %a n %a n %a n %a
ST1424 133 72 56.7 2 1.6 59 18.9
ST17 102 3 2.4 4 3.1 95 30.4
ST796 74 71 55.5 1 100 2 0.6
ST80 52 6 4.7 5 3.9 41 13.1
ST1421 49 37 29.1 12 3.8
ST78 22 21 16.4 1 0.3
Other 136 9 7.1 25 19.5 102 32.7
Total 568 127 100 128 100 1 100 312 100
a Percentage of isolates having the identified sequence type among isolates of major E. faecium sequence types harbouring the 
identified gene(s).
of vanA- or vanB-containing transposons by 
horizontal transfer in CC 17 clones has resulted 
in VRE with pandemic potential.
In AESOP 2019, six E. faecium STs predomi-
nated: ST1424 (of which 54.1% of isolates har-
boured vanA genes and 1.5% vanB genes); ST17 
(2.9% vanA, 3.9% vanB); ST796 (0% vanA, 95.9% 
vanB, 1.4% vanA and vanB); ST80 (11.5% vanA, 
9.6% vanB); ST1421 (75.5% vanA, 0% vanB); and 
ST78 (0% vanA, 95.5% vanB).
Conclusions
The AESOP 2019 study has shown that, although 
still predominately caused by E. faecalis, ente-
rococcal bacteraemia in Australia is frequently 
caused by ampicillin-resistant, high-level 
gentamicin-resistant vancomycin-resistant 
E. faecium. Furthermore, the percentage of 
E. faecium bacteraemia isolates resistant to 
vancomycin in Australia is significantly higher 
than that seen in almost all European countries. 
While the vanB operon was the predominant 
genotype in Australia, in 2019 49.1% of E. faecium 
harboured the vanA gene. In addition to being 
a significant cause of healthcare-associated 
sepsis, the emergence of multiple multi-resistant 
hospital-adapted E. faecium strains has become 
a major infection control issue in Australian 
hospitals. Ongoing studies on the enterococcal 
genome will contribute to our understanding of 
the rapid and ongoing evolution of enterococci 
in the hospital environment and will assist in 
preventing their nosocomial transmission.
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